GR3033488T3 - Compositions for eliciting cytotoxic t-lymphocyte responses against viruses. - Google Patents

Compositions for eliciting cytotoxic t-lymphocyte responses against viruses.

Info

Publication number: GR3033488T3
Authority: GR; Greece
Prior art keywords: compositions; responses against; against viruses; lymphocyte responses; eliciting cytotoxic
Prior art date: 1991-12-02

Application number

GR20000401185T

Other languages

English (en)

Inventor

Jagannadha K Sastry

Ralph B Arlinghaus

Chris D Platsoucas

Pramod N Nehete

Original Assignee

Univ Texas

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-12-02

Filing date

2000-05-24

Publication date

2000-09-29

1991-12-02 Priority claimed from US07/800,932 external-priority patent/US6210873B1/en

2000-05-24 Application filed by Univ Texas filed Critical Univ Texas

2000-09-29 Publication of GR3033488T3 publication Critical patent/GR3033488T3/el

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18822—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18834—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
- G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- G01N2333/16—HIV-1, HIV-2

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Mycology (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Food Science & Technology (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Toxicology (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)

GR20000401185T 1991-12-02 2000-05-24 Compositions for eliciting cytotoxic t-lymphocyte responses against viruses. GR3033488T3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US07/800,932 US6210873B1 (en)	1987-08-28	1991-12-02	Methods and compositions for the priming of specific cytotoxic T-lymphocyte response
US94586592A	1992-09-16	1992-09-16
PCT/US1992/010378 WO1993010816A1 (en)	1991-12-02	1992-12-02	Compositions for eliciting cytotoxic t-lymphocyte responses against viruses

Publications (1)

Publication Number	Publication Date
GR3033488T3 true GR3033488T3 (en)	2000-09-29

Family

ID=27122272

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GR20000401185T GR3033488T3 (en)	1991-12-02	2000-05-24	Compositions for eliciting cytotoxic t-lymphocyte responses against viruses.

Country Status (11)

Country	Link
EP (2)	EP0968721A3 (el)
JP (1)	JPH07502729A (el)
AT (1)	ATE190226T1 (el)
AU (1)	AU666160B2 (el)
CA (1)	CA2124691A1 (el)
DE (1)	DE69230769T2 (el)
DK (1)	DK0671947T3 (el)
ES (1)	ES2145768T3 (el)
GR (1)	GR3033488T3 (el)
PT (1)	PT671947E (el)
WO (1)	WO1993010816A1 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2173138A1 (en) *	1993-10-19	1995-04-27	Masafumi Takiguchi	Peptide capable of inducing immune response against hiv and aids preventive or remedy containing the peptide
CN1230444C (zh)	1998-11-16	2005-12-07	德克萨斯州立大学董事会	含有hiv细胞毒t淋巴细胞表位的hiv多肽或肽或其多聚核苷酸表达构建体的用途
EP1141016A1 (en) *	1998-12-18	2001-10-10	Mount Sinai Hospital	Three dimensional structure of a sterile alpha motif domain
ATE516046T1 (de)	1999-05-13	2011-07-15	Wyeth Corp	Adjuvans kombinationsformulierungen
IL155690A0 (en)	2000-11-10	2003-11-23	Wyeth Corp	Adjuvant combination formulations
RU2214274C2 (ru) *	2001-08-16	2003-10-20	Государственное предприятие Институт иммунологии Федерального управления медико-биологических экстремальных проблем при МЗ РФ	Иммуногенная композиция, содержащая химерный полипептид вич, полипептиды и тест-система для обнаружения антител к вич

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5030449A (en) *	1988-07-21	1991-07-09	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Synthetic vaccine against AIDS virus
WO1989002277A2 (en) *	1987-08-28	1989-03-23	Board Of Regents, The University Of Texas System	Prophylaxis and therapy of acquired immunodeficiency syndrome
US5128319A (en) *	1987-08-28	1992-07-07	Board Of Regents, The University Of Texas System	Prophylaxis and therapy of acquired immunodeficiency syndrome
US5820865A (en) *	1988-01-26	1998-10-13	The United States Of America As Represented By The Department Of Health And Human Services	Method to induce cytotoxic T Lymphocytes specific for a broad array of HIV-1 isolates using hybrid synthetic peptides
EP0339504A3 (en) *	1988-04-26	1990-09-12	The Du Pont Merck Pharmaceutical Company	Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
CA2025634A1 (en) *	1989-09-19	1991-03-20	Thomas Fuerst	Peptides including ctl epitopes of hiv proteins and use thereof
IT1238343B (it) *	1989-10-16	1993-07-13	Cesalpino Andrea Fond	Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche

1992
- 1992-12-02 JP JP5510318A patent/JPH07502729A/ja active Pending
- 1992-12-02 EP EP99112007A patent/EP0968721A3/en not_active Withdrawn
- 1992-12-02 ES ES93900770T patent/ES2145768T3/es not_active Expired - Lifetime
- 1992-12-02 DK DK93900770T patent/DK0671947T3/da active
- 1992-12-02 AT AT93900770T patent/ATE190226T1/de not_active IP Right Cessation
- 1992-12-02 AU AU32339/93A patent/AU666160B2/en not_active Ceased
- 1992-12-02 DE DE69230769T patent/DE69230769T2/de not_active Expired - Fee Related
- 1992-12-02 PT PT93900770T patent/PT671947E/pt unknown
- 1992-12-02 CA CA002124691A patent/CA2124691A1/en not_active Abandoned
- 1992-12-02 WO PCT/US1992/010378 patent/WO1993010816A1/en not_active Ceased
- 1992-12-02 EP EP93900770A patent/EP0671947B1/en not_active Expired - Lifetime
2000
- 2000-05-24 GR GR20000401185T patent/GR3033488T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU3233993A (en)	1993-06-28
DE69230769T2 (de)	2000-07-13
WO1993010816A1 (en)	1993-06-10
DK0671947T3 (da)	2000-07-24
EP0671947B1 (en)	2000-03-08
ES2145768T3 (es)	2000-07-16
AU666160B2 (en)	1996-02-01
EP0968721A3 (en)	2004-02-04
DE69230769D1 (de)	2000-04-13
ATE190226T1 (de)	2000-03-15
CA2124691A1 (en)	1993-06-10
JPH07502729A (ja)	1995-03-23
EP0968721A2 (en)	2000-01-05
PT671947E (pt)	2000-07-31
EP0671947A1 (en)	1995-09-20

Publication	Publication Date	Title
IL100677A0 (en)	1992-09-06	Optically active 5h-pyrrolo(3,4-b)pyrazine derivative,its preparation and pharmaceutical compositions containing it
HU896769D0 (en)	1990-03-28	Fungicide compositions comprising azolylmethylcyclopentane-benzylidene-derivatives as active ingredient and process for preparation of the active ingredients
IL101883A0 (en)	1992-12-30	Antiviral combinations and pharmaceutical compositions containing them
GR3017282T3 (en)	1995-11-30	Novel arylpyridazines, their manufacture, use and medicaments containing them.
IL102310A0 (en)	1993-01-14	Pharmaceutical compositions comprising cyclosporins
CA2108455A1 (en)	1992-10-16	Pharmaceutical compositions against gastric disorders
GR3029791T3 (en)	1999-06-30	Improved immunogenic compositions against human gastrin 17
IL103516A0 (en)	1993-03-15	Cytotoxic bicyclo(7,3,1)tridec-4-ene-2,6-diyne compounds,process for the preparation thereof and pharmaceutical compositions containing them
IL103510A0 (en)	1993-03-15	Pharmaceutical compositions containing antibodies for causing immunosuppression
IL93162A0 (en)	1990-11-05	Anti hiv pharmaceutical compositions
IL98156A0 (en)	1992-06-21	Pharmaceutical compositions containing magnesium-pyridoxal-5'-phosphate-glutaminate
ZA901674B (en)	1990-12-28	Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure(7alpha,17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
HUT66234A (en)	1994-10-28	Process to prepare 4,13-dioxabicyclo(8.2.1)-tridecenon-derivatives and pharmaceutical compositions containing them
EP0509516A3 (en)	1993-01-13	Dental restoration composition
IL92187A0 (en)	1990-07-26	Anti-human immunodeficiency virus compositions comprising fluorine-containing pyridonecarboxylic acid derivatives
GR3033488T3 (en)	2000-09-29	Compositions for eliciting cytotoxic t-lymphocyte responses against viruses.
GB9012993D0 (en)	1990-08-01	Dental compositions
HU9303113D0 (en)	1994-01-28	Pharmaceutical compositions containing 1,2-dithiol-3-thione-derivatives
DK0443848T3 (da)	1994-10-17	Nyt antiulcermiddel
AU587626B2 (en)	1989-08-24	Continuous release peptide composition
IL109866A0 (en)	1994-10-07	Crystalline 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (+) l-hydrogentartrate, its preparation and pharmaceutical compositions containing it
IL101757A0 (en)	1992-12-30	Pharmaceutical compositions containing a 1,3-oxathiolane analogue
IL91813A0 (en)	1990-06-10	Pharmaceutical compositions containing stable oxapenem-3-carboxylic acids and their preparation
AU8251491A (en)	1992-02-27	5'-amine substituted adenosine analogs as immunosuppressants
GR1002385B (el)	1996-07-03	Καθαρη μορφη στρεπτογραμινων, παρασκευη αυτης και φαρμακευτικες συνθεσεις που την περιεχουν.

Legal Events

Date	Code	Title	Description
2006-07-04	ML	Lapse due to non-payment of fees